company background image
CNTX logo

Context Therapeutics NasdaqCM:CNTX Stock Report

Last Price

US$1.38

Market Cap

US$22.1m

7D

20.2%

1Y

128.4%

Updated

27 Mar, 2024

Data

Company Financials +

Context Therapeutics Inc.

NasdaqCM:CNTX Stock Report

Market Cap: US$22.1m

CNTX Stock Overview

Context Therapeutics Inc., a biopharmaceutical company, develops products for the treatment of solid tumors in the United States.

CNTX fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health4/6
Dividends0/6

Context Therapeutics Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Context Therapeutics
Historical stock prices
Current Share PriceUS$1.38
52 Week HighUS$1.69
52 Week LowUS$0.47
Beta2.13
1 Month Change22.29%
3 Month Change20.17%
1 Year Change128.39%
3 Year Changen/a
5 Year Changen/a
Change since IPO-72.90%

Recent News & Updates

We're A Little Worried About Context Therapeutics' (NASDAQ:CNTX) Cash Burn Rate

Mar 27
We're A Little Worried About Context Therapeutics' (NASDAQ:CNTX) Cash Burn Rate

Here's Why Context Therapeutics (NASDAQ:CNTX) Must Use Its Cash Wisely

Sep 28
Here's Why Context Therapeutics (NASDAQ:CNTX) Must Use Its Cash Wisely

Recent updates

We're A Little Worried About Context Therapeutics' (NASDAQ:CNTX) Cash Burn Rate

Mar 27
We're A Little Worried About Context Therapeutics' (NASDAQ:CNTX) Cash Burn Rate

Here's Why Context Therapeutics (NASDAQ:CNTX) Must Use Its Cash Wisely

Sep 28
Here's Why Context Therapeutics (NASDAQ:CNTX) Must Use Its Cash Wisely

Will Context Therapeutics (NASDAQ:CNTX) Spend Its Cash Wisely?

Jun 05
Will Context Therapeutics (NASDAQ:CNTX) Spend Its Cash Wisely?

Context to focus on ELONA trial, CLDN6 program, extends cash runway into 1Q24

Sep 27

We're Keeping An Eye On Context Therapeutics' (NASDAQ:CNTX) Cash Burn Rate

Sep 15
We're Keeping An Eye On Context Therapeutics' (NASDAQ:CNTX) Cash Burn Rate

Context Therapeutics GAAP EPS of -$0.25 in-line

Aug 11

Context Therapeutics, Menarini to collaborate on breast cancer treatment combo trial

Aug 02

Companies Like Context Therapeutics (NASDAQ:CNTX) Are In A Position To Invest In Growth

May 28
Companies Like Context Therapeutics (NASDAQ:CNTX) Are In A Position To Invest In Growth

Context Therapeutics: A New Biotech Issue With A Low Valuation And Significant Potential

Nov 02

Shareholder Returns

CNTXUS PharmaceuticalsUS Market
7D20.2%1.2%0.4%
1Y128.4%25.8%28.8%

Return vs Industry: CNTX exceeded the US Pharmaceuticals industry which returned 23.9% over the past year.

Return vs Market: CNTX exceeded the US Market which returned 29.5% over the past year.

Price Volatility

Is CNTX's price volatile compared to industry and market?
CNTX volatility
CNTX Average Weekly Movement10.7%
Pharmaceuticals Industry Average Movement9.7%
Market Average Movement6.0%
10% most volatile stocks in US Market16.9%
10% least volatile stocks in US Market3.0%

Stable Share Price: CNTX's share price has been volatile over the past 3 months.

Volatility Over Time: CNTX's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
20155Martin Lehrhttps://www.contexttherapeutics.com

Context Therapeutics Inc., a biopharmaceutical company, develops products for the treatment of solid tumors in the United States. It develops CLDN6xCD3 bsAb, an anti-CD3 x anti-Claudin 6 antigen bispecific monoclonal antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of an anti-claudin 6 bispecific monoclonal antibody for cancer therapy.

Context Therapeutics Inc. Fundamentals Summary

How do Context Therapeutics's earnings and revenue compare to its market cap?
CNTX fundamental statistics
Market capUS$22.07m
Earnings (TTM)-US$23.96m
Revenue (TTM)n/a

0.0x

P/S Ratio

-0.9x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
CNTX income statement (TTM)
RevenueUS$0
Cost of RevenueUS$0
Gross ProfitUS$0
Other ExpensesUS$23.96m
Earnings-US$23.96m

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-1.50
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0%

How did CNTX perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.